IPOs: The 5 Best New Stocks of Q1 2014

Pharmaceutical companies dominate the list of best IPOs

       

New Stocks — Auspex Pharmaceuticals (ASPX)

Auspex 185 IPOs: The 5 Best New Stocks of Q1 2014IPO Return: 147.1%

The runner-up on our list of best new stocks is Auspex Pharmaceuticals (ASPX). This is a biotech operator that develops drugs for orphan diseases, which are those that impact fewer than 200,000 people in the U.S. For the most part, the focus is on hyperkinetic movement disorders. Examples include chorea associated with Huntington’s disease and Tourette syndrome.

Right now, the company’s lead drug is SD-809, a chorea treatment which is currently in Phase 3 registration. The only other competing, FDA-approved drug is Tetrabenazine. Auspex’s version is expected to allow for less dosing and better results.

If everything goes fine, the drug could hit the market in by 2015.

At the same time, the company is in a Phase 2 trial for another use of SD-809 — that is, for the treatment of tardive dyskinesia. The data will be available in the middle of next year.


Article printed from InvestorPlace Media, http://investorplace.com/ipo-playbook/ipos-best-new-stocks-q1-2014/.

©2014 InvestorPlace Media, LLC

Comments are currently unavailable. Please check back soon.